Granite Bio AG

Granite Bio is at the forefront of biotechnological innovation, concentrating on the treatment of chronic inflammatory, autoimmune, and fibrotic diseases. These conditions are prevalent as they lack effective therapeutic options, resulting in substantial global mortality rates. The company has developed two pioneering antibodies, GRT-001 and GRT-002, which target the fundamental disease biology of these systemic conditions. GRT-001 operates by depleting pathogenic pro-inflammatory monocytes utilizing novel mechanisms like ADCC/ADCP, earning it the title of an `Innate Rituximab.` GRT-002 is notable for targeting newly discovered disease biology nodes, identified through proprietary patient profiling tactics. Granite Bio`s research is built on a deep foundation of understanding disease mechanisms, with its team drawing expertise from prestigious scientific backgrounds, supporting impactful advances in immunology and translational medicine.